DIPHENYL ETHER COMPOUNDS FOR THE TREATMENT OF LIVER, LUNG DISORDERS, DIABETIC COMPLICATIONS AND CARDIOVASCULAR DISEASES
Described herein are compounds of formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof, for use in treating liver diseases such as non-alcoholic fatty liver disea...
Saved in:
Main Authors | , , , , , |
---|---|
Format | Patent |
Language | English French |
Published |
02.02.2012
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Described herein are compounds of formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof, for use in treating liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), and other fibrotic diseases of the liver; diabetic complications such as macro (ischemic heart disease, cerebrovascular disease and peripheral vascular disease) and micro (cataract, retinopathy nephropathy neuropathy, maculopathy and glaucoma) vascular complication; and cardiovascular diseases such as atherosclerosis, restenosis, hypertension, vasospasm, and cardiac hypertrophy; and lung disorders and lung fibrosis.
La présente invention concerne des composés de formule (I), leurs dérivés, analogues, formes tautomères, stéréoisomères, formes polymorphiques, hydrates, solvates, compositions et sels de qualité pharmaceutique, métabolites et promédicaments pour emploi dans le traitement de pathologies hépatiques telles que la stéatose hépatique non alcoolique (NAFLD) et la stéato-hépatite non alcoolique (SHNA), et d'autres maladies fibrotiques du foie ; de complications diabétiques telles que les complications macrovasculaires (cardiopathie ischémique, maladie vasculaire cérébrale et maladie vasculaire périphérique) et microvasculaires (cataractes, rétinopathie, néphropathie, neuropathie, maculopathie et glaucome) ; et de maladies cardio-vasculaires telles qu'athérosclérose, resténose, hypertension, vasospasme et hypertrophie cardiaque ; et de troubles pulmonaires et de fibrose pulmonaire. |
---|---|
Bibliography: | Application Number: WO2011IN00210 |